[1] |
Greb JE, Goldminz AM, Elder JT, et al. Psoriasis[J]. Nat Rev Dis Primers, 2016,2:16082. doi: 10.1038/nrdp.2016.82.<br />
|
[2] |
Tonel G, Conrad C. Interplay between keratinocytes and immune cells⁃⁃recent insights into psoriasis pathogenesis[J]. Int J Biochem Cell Biol, 2009,41(5):963⁃968. doi: 10.1016/j.biocel.2008.10.022.<br />
|
[3] |
Zenz R, Eferl R, Kenner L, et al. Psoriasis⁃like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins[J]. Nature, 2005,437(7057):369⁃375. doi: 10.1038/nature03963.<br />
|
[4] |
Zenz R, Eferl R, Scheinecker C, et al. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease[J]. Arthritis Res Ther, 2008,10(1):201. doi: 10.1186/ar2338.<br />
|
[5] |
Johansen C, Kragballe K, Rasmussen M, et al. Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin[J]. Br J Dermatol, 2004,151(3):600⁃607. doi: 10.1111/j.1365⁃2133.2004.06088.x.<br />
|
[6] |
Haider AS, Duculan J, Whynot JA, et al. Increased JunB mRNA and protein in psoriasis vulgaris lesions[J]. J Invest Dermatol, 2006,126(4):912⁃914. doi: 10.1038/sj.jid.5700183.<br />
|
[7] |
Shi ZR, Tan GZ, Cao CX, et al. Decrease of galectin⁃3 in keratinocytes: a potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis[J]. J Autoimmun, 2018,89:30⁃40. doi: 10.1016/j.jaut.2017.11.002.<br />
|
[8] |
Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratino⁃cytes and immunocytes required for development of psoriasis in a novel transgenic mouse model[J]. Nat Med, 2005,11(1):43⁃49. doi: 10.1038/nm1162.<br />
|
[9] |
Gao Q, Liang X, Shaikh AS, et al. JAK/STAT signal transduction: promising attractive targets for immune, inflammatory and hemato⁃poietic diseases[J]. Curr Drug Targets, 2018,19(5):487⁃500. doi: 10.2174/1389450117666161207163054.<br />
|
[10] |
Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA⁃21, a Stat3 inhibitor[J]. J Invest Dermatol, 2011,131(1):108⁃117. doi: 10.1038/jid.2010.255.<br />
|
[11] |
Nakajima K, Sano S. Mouse models of psoriasis and their relevance[J]. J Dermatol, 2018,45(3):252⁃263. doi: 10.1111/1346⁃8138. 14112.<br />
|
[12] |
Hirai T, Kanda T, Sato K, et al. Cathepsin K is involved in develop⁃ment of psoriasis⁃like skin lesions through TLR⁃dependent Th17 activation[J]. J Immunol, 2013,190(9):4805⁃4811. doi: 10.4049/jimmunol.1200901.<br />
|
[13] |
Takaishi M, Nakajima K, Ouyang W, et al. Psoriasis⁃like skin lesions are dependent on IL⁃23 but develop in the absence of IL⁃22 in a model mouse[J]. J Dermatol Sci, 2014,73(3):261⁃264. doi: 10.1016/j.jdermsci.2013.11.008.<br />
|
[14] |
Yamamoto M, Nakajima K, Takaishi M, et al. Psoriatic inflam⁃mation facilitates the onset of arthritis in a mouse model[J]. J Invest Dermatol, 2015,135(2):445⁃453. doi: 10.1038/jid.2014.426.<br />
|
[15] |
Pasparakis M, Courtois G, Hafner M, et al. TNF⁃mediated inflamma⁃tory skin disease in mice with epidermis⁃specific deletion of IKK2[J]. Nature, 2002,417(6891):861⁃866. doi: 10.1038/nature00820.<br />
|
[16] |
Stratis A, Pasparakis M, Rupec RA, et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte⁃induced psoriasis⁃like skin inflammation[J]. J Clin Invest, 2006,116(8):2094⁃2104. doi: 10.1172/JCI27179.<br />
|
[17] |
Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis[J]. Blood, 2003, 102(1):161⁃168.<br />
|
[18] |
Voskas D, Jones N, Van Slyke P, et al. A cyclosporine⁃sensitive psoriasis⁃like disease produced in Tie2 transgenic mice[J]. Am J Pathol, 2005,166(3):843⁃855. doi: 10.1016/S0002⁃9440(10)62305⁃X.<br />
|
[19] |
Danilenko DM. Review paper: preclinical models of psoriasis[J]. Vet Pathol, 2008,45(4):563⁃575. doi: 10.1354/vp.45⁃4⁃563.<br />
|
[20] |
Swindell WR, Johnston A, Carbajal S, et al. Genome⁃wide profiling of five mouse models identifies similarities and differences with human psoriasis[J]. PLoS One, 2011,6(4):e18266. doi: 10.1371/journal.pone.0018266.<br />
|
[21] |
Bocheńska K, Smolińska E, Moskot M, et al. Models in the research process of psoriasis[J]. Int J Mol Sci, 2017,18(12):2514. doi: 10.3390/ijms18122514.<br />
|
[22] |
Schön MP. Animal models of psoriasis: a critical appraisal[J]. Exp Dermatol, 2008,17(8):703⁃712. doi: 10.1111/j.1600⁃0625. 2008.00751.x.<br />
|
[23] |
Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte over of IL⁃17C promotes psoriasiform skin inflammation[J]. J Immunol, 2013,190(5):2252⁃2262. doi: 10.4049/jimmunol.1201505.<br />
|
[24] |
Shepherd J, Little MC, Nicklin MJ. Psoriasis⁃like cutaneous inflammation in mice lacking interleukin⁃1 receptor antagonist[J]. J Invest Dermatol, 2004,122(3):665⁃669. doi: 10.1111/j.0022⁃ 202X.2004.22305.x.<br />
|